- Trials with a EudraCT protocol (116)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (17)
116 result(s) found for: Iron lung.
Displaying page 1 of 6.
EudraCT Number: 2018-002366-39 | Sponsor Protocol Number: 000000 | Start Date*: 2018-08-23 | |||||||||||
Sponsor Name:University of Oxford / Clinical Trials and Research Governance | |||||||||||||
Full Title: A pilot trial of intravenous iron for the treatment of iron deficiency in adult patients with cystic fibrosis | |||||||||||||
Medical condition: Cystic fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000130-33 | Sponsor Protocol Number: ORION-HF | Start Date*: 2022-12-23 | ||||||||||||||||||||||||||
Sponsor Name:Hannover Medical School | ||||||||||||||||||||||||||||
Full Title: A pilot study to explore safety, tolerability and efficacy of ORal IrON supplementation with ferric maltol in treating iron deficiency and anaemia in patients with Heart Failure (ORION-HF) | ||||||||||||||||||||||||||||
Medical condition: Patients with heart failure, iron deficiency and anaemia with either reduced or preserved left ventricular ejection fraction | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001238-89 | Sponsor Protocol Number: FACE | Start Date*: 2016-06-15 |
Sponsor Name:Consorci Mar Parc de Salut de Barcelona (Parc de Salut MAR) | ||
Full Title: IRON DEFICIENCY IN PATIENTS WITH COPD: IMPACT OF TOPPING WITH IRON CARBOXYMALTOSE. FACE STUDY (ASSESSMENT IN PATIENTS WITH FERINJECT AND IRON DEFICIENCY COPD TO IMPROVE EXERCISE TOLERANCE) | ||
Medical condition: Iron deficiency in Chronic obstructive pulmonary disease patients (COPD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-002952-17 | Sponsor Protocol Number: COPDIron | Start Date*: 2012-11-12 |
Sponsor Name:University of Oxford | ||
Full Title: Effects of intravenous iron on hypoxic pulmonary responses in COPD | ||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-000829-39 | Sponsor Protocol Number: 2016LF003B | Start Date*: 2016-11-10 | |||||||||||
Sponsor Name:Royal Brompton and Harefiled NHS Foundation Trust, Royal Brompton Hospital | |||||||||||||
Full Title: Iron and Chronic Obstructive Pulmonary Disease (COPD) Exercise Trial | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003659-52 | Sponsor Protocol Number: PULSE | Start Date*: 2018-04-02 | |||||||||||
Sponsor Name:António Robalo Nunes | |||||||||||||
Full Title: Impact of Iron Deficiency treatment with intravenous ferric carboxymaltose in patients with Chronic Obstructive Pulmonary Disease: an open-label, randomized, 2-arm, no treatment control, parallel s... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease and Iron Deficiency | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-005005-43 | Sponsor Protocol Number: FACEII | Start Date*: 2022-06-06 | |||||||||||
Sponsor Name:Consorci Mar Parc de Salut de Barcelona | |||||||||||||
Full Title: Ferinject in Addition to pulmonary rehabilitation in patients with COPD and iron deficiency to improve Exercise tolerance (FACE II study) | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000634-11 | Sponsor Protocol Number: MEK114653 | Start Date*: 2011-07-12 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A Phase II, Open-label, Multicenter, Randomized Study to Assess the Efficacy and Safety of GSK1120212 Compared with Docetaxel in 2nd Line Subjects with Targeted Mutations (KRAS, NRAS, BRAF, MEK1) i... | |||||||||||||
Medical condition: In 2nd Line Subjects with Targeted Mutations (KRAS, NRAS, BRAF, MEK1) in Locally Advanced or Metastatic Nonsmall Cell Lung Cancer (NSCLC Stage IIIBwet-IV). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) ES (Temporarily Halted) NL (Prematurely Ended) IT (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000779-40 | Sponsor Protocol Number: VEG109611 | Start Date*: 2008-07-08 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A Phase II Trial of Pazopanib, a Pan Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitor, in Relapsed or Refractory Small Cell Lung Cancer (SCLC) | |||||||||||||
Medical condition: Relapsed or Refractory Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-007520-17 | Sponsor Protocol Number: 800088NAP2001 | Start Date*: 2008-07-25 | ||||||||||||||||||||||||||
Sponsor Name:Janssen-Cilag International N.V, Turnhoutseweg 30, 2340 Beerse, Belgium | ||||||||||||||||||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Parallel Group Study to Evaluate the Effect of RWJ-800088 on The Prevention of Chemotherapy-Induced Anemia and The Prevention of Chemotherapy-Induced Thromb... | ||||||||||||||||||||||||||||
Medical condition: Chemotherapy induced anaemia and chemotherapy induced thrombocytopenia | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: BE (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002472-34 | Sponsor Protocol Number: EGF109462 | Start Date*: 2007-08-06 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Limited | |||||||||||||
Full Title: A single-arm, two-stage Phase II study of Lapatinib and Pemetrexed in the second line treatment of advanced or metastatic Non-Small Cell Lung Cancer | |||||||||||||
Medical condition: Patients with advanced or metatstatic Non-Small Cell Lung Cancer who have received one prior platinum containing chemotherapy regimen | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000927-42 | Sponsor Protocol Number: HZC116601 | Start Date*: 2012-10-19 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Ltd | |||||||||||||
Full Title: A Randomised, Double-Blind, Placebo-Controlled, Cross-Over, Single-Centre Study to Investigate the Acute Lung Deflation Effects of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg Once Da... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003510-41 | Sponsor Protocol Number: 200163 | Start Date*: 2014-01-24 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A two part, Phase IIa, randomized, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical efficacy of oral danirixin (GSK1325756) in symp... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004297-98 | Sponsor Protocol Number: 117113 | Start Date*: 2014-09-01 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: Study 117113: Mepolizumab vs. Placebo as add-on treatment for frequently exacerbating COPD patients characterized by eosinophil level. | |||||||||||||
Medical condition: Treatment of severe Chronic Obstructive Pulmonary Disease (COPD) in patients presenting frequent exacerbations | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) SK (Completed) DE (Completed) GB (Completed) DK (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004865-10 | Sponsor Protocol Number: SFA100062 | Start Date*: 2016-12-08 |
Sponsor Name:GlaxoSmithKiline Research and Development LTD. | ||
Full Title: A Randomized, Parallel Group, Double-Blind, Comparative Trial Assessing Lung Function and Other Measures of Asthma Control in Adults and Adolescents, at least 12 Years of Age, with Asthma, Who Have... | ||
Medical condition: Asthma | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2012-003106-27 | Sponsor Protocol Number: RLV116974 | Start Date*: 2012-11-01 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared with Fluticasone Propionate/Salmeterol ... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004298-28 | Sponsor Protocol Number: MEA117106 | Start Date*: 2014-05-02 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: Study MEA117106: Mepolizumab vs. Placebo as add-on treatment for frequently exacerbating COPD patients. | |||||||||||||
Medical condition: Treatment of severe Chronic Obstructive Pulmonary Disease (COPD) in patients presenting frequent exacerbations | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) CZ (Completed) PL (Completed) IT (Completed) BE (Completed) ES (Completed) EE (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000884-42 | Sponsor Protocol Number: 201316 | Start Date*: 2014-09-12 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A Randomized, Blinded, Double-dummy, Parallel-group Study to Evaluate the Efficacy and Safety of Umeclidinium (UMEC) 62.5 mcg compared with Tiotropium 18 mcg in Subjects with Chronic Obstructive Pu... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000643-33 | Sponsor Protocol Number: TFR116341 | Start Date*: 2014-08-26 | ||||||||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||||||||||||||||||
Full Title: A Placebo Controlled, Double-blind, Multi-centre, Single Dose, Parallel Group, Randomised Clinical Trial of GSK2862277 in Patients undergoing Oesophagectomy Surgery. | ||||||||||||||||||
Medical condition: Prevention and treatment of Acute Respiratory Distress Syndrome (ARDS) and other acute inflammatory conditions | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-002452-13 | Sponsor Protocol Number: HZC115151 | Start Date*: 2012-01-10 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A 12-month, open label, randomised, effectiveness study to evaluate fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) Inhalation Powder delivered once daily via a Novel Dry Powder Inhale... | |||||||||||||
Medical condition: Subjects with Chronic Obstructive Pulmonary Disease (COPD). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
